Last month we brought to you the first in a series of webinars "The Ultimate Guide to Lateral Flow." The event was a great success with attendees from all over the world logging on to hear about lateral flow and considerations when embarking on a development project. Darren Rowles, BBI's Product Manager for Lateral Flow and Gold Nanoparticles, hosted the session and was joined by Karen Whiting the Global Head of New Product Development whose team were responsible for developing Morffi: Signal Enhancement technology. A live Q&A session unearthed some interesting questions, so we thought we’d summarise them for you.
Presenting at a recent ‘Lateral Flow Test Development Workshop’ hosted by BBI Solutions, Merck and Kinematic Automation, Chris Walkinshaw showcased a variety of ‘Real Life Lateral Flow Case Studies.’ We caught up with Chris for him to share some insight into his experience, development advice and predictions for the future.
At AACC, 1st-3rd August in San Diego, USA, BBI Solutions held a breakfast seminar on our Morffi™ signal enhancement technology: an evolution in assay development, and they presented their poster: Increasing the limit of detection and performance of rapid immunological tests. At the end of the seminar and poster session, many questions were asked about the Morffi technology. Here are our answers.
A good partnership is the cornerstone of most successful businesses, it’s often the catalyst that brings original ideas to life and transforms concept to reality. Nikki Robinson, Head of Reagents explains how our custom conjugation scientists are an expert team that deeply understands the power of partnership.
Quality raw materials are the base that all great products depend on, but surprisingly, this is part of the process that many companies - particularly those launching a new product or exploring a new direction - take for granted and fail to investigate thoroughly enough.
With flu seasons now lasting longer, early and accurate diagnosis is crucial to identifying and rapidly treating infections. "Mobile enabled diagnostics will have a key role to play in combatting influenza outbreaks" says Neil Polwart, Novarum founder and BBI Group Head of Mobile.
One of the most common questions I get when discussing antibody development is: which is better a monoclonal or polyclonal antibody? The simple answer is, it depends on the application. For example, if specificity is the driving factor then a monoclonal antibody likely is your best bet; however, if you are looking to use the same antibody source for several applications, a polyclonal may best serve your needs.